Renalytix to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 08, 2022 07:00 ET
|
Renalytix plc
NEW YORK and SALT LAKE CITY, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the company will participate in a fireside chat at the H.C. Wainwright 24th...
Data Results Published in American Journal of Managed Care demonstrate adoption and clinical utility of KidneyIntelX™ with Primary Care Physicians
August 08, 2022 07:00 ET
|
Renalytix plc
98% of 401 Primary Care Physicians confirmed KidneyIntelX has value as a risk decision tool in their adult patients with type 2 diabetes and chronic kidney disease stages 1-3b. Published study...
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2022
June 30, 2022 07:00 ET
|
Renalytix plc
LONDON and SALT LAKE CITY, June 30, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical...
Renalytix to Report Financial Results for Third Quarter Fiscal 2022 on June 30
June 23, 2022 07:00 ET
|
Renalytix plc
NEW YORK and SALT LAKE CITY, June 23, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its third quarter fiscal 2022 financial results on...
1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX™ Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients
June 10, 2022 07:00 ET
|
Renalytix plc
NEW YORK and SALT LAKE CITY, June 10, 2022 (GLOBE NEWSWIRE) -- Deployment of Renalytix’s (NASDAQ: RNLX) (LSE: RENX) KidneyIntelXTM bioprognosticTM testing in 1,112 adult diabetic kidney disease...
Renalytix to Present at 42nd Annual William Blair Growth Stock Conference
June 08, 2022 07:00 ET
|
Renalytix plc
NEW YORK and SALT LAKE CITY, June 08, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will present at the 42nd Annual William Blair Growth Stock...
KidneyIntelX™ Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort
June 06, 2022 07:00 ET
|
Renalytix plc
Data shared in oral presentation at American Diabetes Association 82nd Scientific Sessions® and published in Kidney360 highlights importance in early understanding of cardiovascular risk, a leading...
Renalytix Announces Two Data Presentations on KidneyIntelX™ at American Diabetes Association 82nd Scientific Sessions®
June 02, 2022 07:00 ET
|
Renalytix plc
Real-world clinical utility in 1,112 patients tested with KidneyIntelX KidneyIntelX stratification for cardiovascular risk in 1,278 diabetic kidney disease patients NEW YORK and SALT LAKE CITY,...
Renalytix plc successful completion of $30.0 million financing package
April 08, 2022 07:00 ET
|
Renalytix plc
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR IN OR...
Renalytix plc Issue of shares
April 08, 2022 07:00 ET
|
Renalytix plc
NEW YORK and SALT LAKE CITY, April 08, 2022 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) announces that under the Company's Employee Share Purchase Plan (the "ESPP"), 22,814 new...